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ORIGINAL RESEARCH
One- Year Mortality After Intensification of 
Outpatient Diuretic Therapy
Christian Madelaire , MD; Finn Gustafsson, MD, PhD, DMSc; Lynne Warner Stevenson, MD;  
Søren Lund Kristensen, MD, PhD; Lars Køber, MD, DMSc; Julie Andersen, MScPH; Maria D’Souza, MD, PhD;  
Tor Biering-Sørensen, MD, PhD; Charlotte Andersson, MD, PhD; Christian Torp-Pedersen, MD, DMSc;  
Gunnar Gislason, MD, PhD; Morten Schou, MD, PhD
BACKGROUND: Mortality is increased following a hospitalization for decompensated heart failure (HF), during which diuretics are 
usually intensified. It is unclear how risk is affected after outpatient intensification of diuretic therapy for HF.
METHODS AND RESULTS: From nationwide administrative registers, we identified all Danish patients who were diagnosed with 
HF from 2001 to 2016 and received angiotensin- converting enzyme inhibitor/angiotensin receptor blocker and β blocker within 
120 days. Subsequent follow- up tracked progressive events of diuretic intensification and HF hospitalization. Intensification 
events were defined as new addition or doubling of loop diuretic or addition of thiazide to loop diuretic. These events were 
included in multivariable Cox regression models, calculating 1- year mortality hazard after each year since inclusion. Patients 
with an intensification event or hospitalization were risk set matched to 2 nonworsened HF controls and absolute 1- year mor-
tality risks were calculated using Kaplan- Meier estimates. We included 74 990 patients, their median age was 71 years, and 
36% were women. Intensification events were associated with significantly increased mortality at all times during follow- up. 
One- year mortality was 18.0% after an intensification event, 22.6% after HF hospitalization, and 10.4% for matched controls 
with neither. In a multivariable Cox model adjusted for age, sex, ischemic heart disease, atrial fibrillation, chronic obstructive 
pulmonary disease, and diabetes mellitus, the hazard ratio for 1- year death after an intensification event was 1.75 (95% CI, 
1.66–1.85), and it was 2.28 (95% CI, 2.16–2.41) after HF hospitalization.
CONCLUSIONS: In a nationwide cohort of patients with HF, outpatient intensification events were associated with almost 2- fold 
risk of mortality during the next year. Although HF hospitalization was associated with a higher risk, the need to intensify diuret-
ics in the outpatient setting is a signal to review and intensify efforts to improve HF outcomes.
Key Words: diuretics ■ heart failure ■ hospitalization ■ mortality ■ outpatient
See Editorial by Khan et al.
Hospitalizations for decompensated heart failure (HF) are associated with increased mortality risk after discharge.1,2 As one of the main interventions 
during HF hospitalization is intensification of diuretic ther-
apy, this intervention may confer increased risk even in 
the absence of hospitalization, as recently demonstrated 
in the PARADIGM- HF (Prospective Comparison of ARNI 
[Angiotensin Receptor–Neprilysin Inhibitor] With ACEI 
[Angiotensin- Converting Enzyme Inhibitor] to Determine 
Impact on Global Mortality and Morbidity in Heart Failure) 
trial setting,3,4 in which patients were followed up, exam-
ined, and evaluated per protocol by investigators sup-
ported in a clinical trial environment. In everyday practice, 
patients with HF are characterized by higher age and 
burden of comorbidities, and decisions about diuretic 
therapy may have different implications for prognosis.
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Data on how often oral diuretic therapy is intensi-
fied without hospitalization are sparse. Higher doses of 
loop diuretics are associated with increased mortality,5 
but whether this is caused by the dose increase or the 
clinical instability that triggered the dose increase is not 
fully understood.6 Increasing occurrence of treatment 
for fluid retention without hospitalization may lead to 
underestimation of the rate of HF progression if only 
hospitalization is considered a marker of risk. Even 
with use of guideline- directed medical therapy and 
patient education, patients may still progress to stage 
D HF in an outpatient setting.7 One clue to such pro-
gression may be intensification of diuretic therapy, trig-
gered by members of the HF care team, by physicians 
outside the HF team, or by the patients themselves. To 
not miss an opportunity to recognize and address de-
velopment of advanced HF in outpatients, it is crucial 
to understand how often outpatient intensification of 
oral diuretic therapy occurs in clinical practice and the 
prognostic implications of these intensification events.
Consequently, the aim of this study was to de-
termine the frequency and subsequent mortality for 
patients after an outpatient intensification event com-
pared with HF hospitalization.
METHODS
The study was a retrospective cohort study based on 
nationwide Danish administrative registers. The data 
were provided by Statistics Denmark, and cannot 
be made available alongside the article. All patients 
with incident HF were identified using International 
Classification of Diseases, Tenth Revision (ICD-10; 
coded I50 [HF] and I42 [cardiomyopathy]), in the 
National Patient Register, which holds information on 
all hospital contacts, inpatient and outpatient, since 
1978.8,9 As we focused on the trajectory for patients 
who were initially stabilized onto recommended ther-
apies, we enrolled those who were alive at 4 months 
after diagnosis, had not had a HF hospitalization 
since diagnosis, and were treated with ACEI/angio-
tensin receptor blocker and β- blocker therapy. If a 
patient had a new HF hospitalization during the ini-
tial 4 months, the patient would have inclusion post-
poned for an additional 4  months. Information on 
medical use was obtained from the National Register 
of Medicinal Products Statistics, where all collected 
prescriptions have been registered since 1995. 
This medical inclusion criterion increased the likeli-
hood of HF with reduced ejection fraction, as data 
on left ventricular ejection fraction were not available. 
Information on birth, migration, and death was ob-
tained from the Central Person Register. The Danish 
Civil Registration System enabled us to identify a 
person in several registers, so the only patients lost 
to follow- up were those leaving the country. The pa-
tients were followed up for 5 years or until the end of 
2017, death, or migration, whichever came first.
Baseline medical therapy was defined as mini-
mum one claimed prescription within 180 days be-
fore inclusion. Baseline comorbidity was defined as 
inpatient or outpatient diagnoses within 5 years be-
fore inclusion.
Outcomes of interest during follow- up were inten-
sification events (defined below) and overnight hospi-
talizations with HF as primary diagnosis at discharge. 
The primary end point was all- cause mortality.
Intensification Events
Intensification events were defined as newly prescribed 
peroral loop diuretics of minimum 80 mg/d furosemide 
equivalent or doubled dosage of furosemide equivalent 
compared with initial dosage to minimum 160  mg/d 
or newly prescribed thiazide in addition to ≥160 mg/d 
furosemide. To reduce the risk of underclassification, 
if a patient was hospitalized with HF within 30  days 
after an intensification event, the patient was only con-
sidered as having a HF hospitalization. Intensification 
CLINICAL PERSPECTIVE
What Is New?
• Outpatient diuretic intensification events are fre-
quent among patients with heart failure and are 
associated with a significantly elevated mortality 
risk.
What Are the Clinical Implications?
• Patients with an outpatient intensification event 
should receive as careful a reevaluation for op-
timization of drug therapy and consideration of 
advanced options as patients who are hospital-
ized for worsening heart failure.
Nonstandard Abbreviations and Acronyms
ACEI  angiotensin-converting enzyme 
inhibitor
COPD  chronic obstructive pulmonary 
disease
DOSE  Diuretic Optimization Strategies 
Evaluation
HF heart failure
ICD-10  International Classification of 
Diseases, Tenth Revision
PARADIGM-HF  Prospective Comparison of 
ARNI With ACEI to Determine 
Impact on Global Mortality and 
Morbidity in Heart Failure
D
ow
nloaded from
 http://ahajournals.org by on A
ugust 20, 2020
J Am Heart Assoc. 2020;9:e016010. DOI: 10.1161/JAHA.119.016010 3
Madelaire et al Mortality After Intensified Diuretic Therapy
of diuretic therapy during a hospitalization was not 
adressed, as data on in- hospital treatment were not 
available.
Statistical Analysis
Baseline characteristics were presented as number and 
percentage for categorical variables and median and 
interquartile range for continuous variables. Incidences 
of intensification events and HF hospitalizations were 
presented as events per 100 person- years. For the main 
analysis, we followed up the patients for 5  years after 
inclusion. After each year period, patients were subdi-
vided into groups on the basis of status: no worsening, 
intensification event, HF hospitalization, or both types of 
worsening. Differences in 1- year mortality hazard rates 
were assessed using multivariable Cox regression mod-
els, adjusted for age, sex, diabetes mellitus, chronic 
obstructive pulmonary disease (COPD), ischemic heart 
disease, previous myocardial infarction, atrial fibrillation, 
and stroke. Patients with a worsening event 1 year were 
not included in the analyses for subsequent years. In 
this analysis, a person could only contribute to an analy-
sis if the person survived until the end of the given time 
period, and differences could be underestimated if one 
worsening event type was associated with a higher mor-
tality hazard immediately after the event than the other. 
Therefore, in a secondary analysis, we matched each 
patient with an intensification event or a hospitalization 
Figure 1. Diagram showing selection of study population.
*Patients who were readmitted within the initial 120 days, followed up for an additional 120 days, and 
had a second (or third, if diagnosed as inpatient) hospitalization. ACEI indicates angiotensin- converting 
enzyme inhibitor; ARB, angiotensin receptor blocker; and BB, β blocker.
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with 2 controls from the study population, using the risk 
set matching principle. Absolute risk of 1- year mortality 
was assessed using the Kaplan- Meier estimator, and 
differences were assessed with multivariable Cox re-
gression models, adjusted for age, sex, diabetes melli-
tus, COPD, ischemic heart disease, previous myocardial 
infarction, atrial fibrillation, and stroke. All Cox regression 
models fulfilled the proportional hazard assumption. The 
level of statistical significance was set to 5%. All analyses 
were conducted in SAS version 9.4 (SAS Institute) and R 
version 3.5.1.10
Ethical Approval 
The present study was based on anonymous data 
from the Danish nationwide administrative registers 
and, therefore, approval from the local ethics com-
mittee was not necessary. The study was approved 
by the Danish Data Protection Agency (project No. 
P- 2019- 262).
RESULTS
Study Population
We identified 192 706 patients with incident HF in the 
period from 2001 to 2016. After exclusion of 37 603 
patients who died at hospital or during the initial 
4  months or migrated, exclusion of 79  096 patients 
who did not receive treatment with ACEI/angiotensin 
receptor blocker and β blocker, and exclusion of 1017 
patients who were considered unstable because of 
early repetitive hospital admissions, 74  990 patients 
were included in the study (Figure 1). The median age 
was 71 years, and 36% were women. Half of the popu-
lation had a history of ischemic heart disease, and a 
third had known history of atrial fibrillation (Table).
Worsening Events
Both intensification events and hospitalizations were 
common early during follow- up, with the highest 
Table. Baseline Characteristics for All Included Patients and Stratified on Worsening Status After the First Year Among 
Patients Still Alive After the First Year (n=62 413)
Characteristic
All Patients
No Worsening 
Event
Intensification Event, 
Outpatient HF Hospitalization Both Events
(N=74 990) (N=53 794) (N=4517) (N=3160) (N=942)
Demographics
Age, y 71 (62–78) 70 (61–78) 72 (64–80) 70 (60–77) 72 (63–80)
Female sex 27 088 (36) 19 160 (36) 1695 (38) 963 (30) 317 (34)
Nursing home 3906 (5) 2595 (5) 286 (6) 117 (4) 56 (6)
Inpatient primary 
diagnosis
50 210 (67) 35 153 (65) 2949 (65) 2024 (64) 588 (62)
Comorbidity
Ischemic heart 
disease
38 178 (51) 27 529 (51) 2379 (53) 1661 (53) 514 (55)
Previous myocardial 
infarction
21 459 (29) 15 626 (29) 1229 (27) 878 (28) 240 (25)
Atrial fibrillation 25 336 (34) 17 589 (33) 1493 (33) 970 (31) 336 (36)
Stroke 6888 (9) 4504 (8) 458 (10) 294 (9) 100 (11)
Diabetes mellitus 14 087 (19) 9243 (17) 1070 (24) 673 (21) 247 (26)
COPD 7711 (10) 4850 (9) 546 (12) 313 (10) 109 (12)
Chronic renal disease 2955 (4) 1592 (3) 291 (6) 113 (4) 49 (5)
Malignancy 3319 (4) 3029 (6) 289 (6) 152 (5) 47 (5)
Medical therapy
MRA 24 217 (32) 16 571 (31) 1418 (31) 1372 (43) 345 (37)
Loop diuretics 53 137 (71) 36 830 (68) 3167 (70) 2541 (80) 676 (72)
Thiazide diuretics 16 472 (22) 11 860 (22) 1165 (26) 625 (20) 259 (27)
Digoxin 17 864 (24) 12 662 (24) 1087 (24) 698 (22) 232 (25)
Aspirin 51 077 (68) 37 135 (69) 3179 (70) 2176 (69) 667 (71)
Statins 44 595 (59) 32 413 (60) 2715 (60) 1976 (63) 573 (61)
Warfarin 22 397 (30) 16 598 (31) 1350 (30) 968 (31) 306 (32)
Nonmedical therapy
ICD/CRT 4047 (5) 2982 (6) 216 (5) 195 (6) 52 (6)
Data are given as median (interquartile range) or number (percentage). COPD indicates chronic obstructive pulmonary disease; CRT, cardiac resynchronization 
therapy; HF, heart failure; ICD, implantable cardioverter- defibrillator; and MRA, mineralocorticoid receptor antagonist.
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incidence rates observed within the first year of follow-
 up (9 per 100 person- years intensification events and 
7 per 100 person- years HF hospitalizations), and more 
stable, lower incidence rates for the following 4 years 
(Figure  2A). Only 2% of the hospitalizations were 
preceded by an intensification event within 30 days. The 
patient status at any time during follow- up is illustrated 
in Figure 2B.
Compared with patients with a HF hospitaliza-
tion within the first year of follow- up, patients with 
Figure 2. Incidence of worsening, patient status during follow- up, and associated death rates.
A, Incidences of intensification events and heart failure (HF) hospitalizations according to years since 
HF diagnosis. B, Multistate model showing how many patients are in the 5 possible states at any time 
during 5 years of follow- up. Arrows indicate how many patients die from each state and death rates per 
100 person- years (P.Y.).
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intensification events were slightly older and were 
more frequently living in a nursing home. The fre-
quency of mineralocorticoid receptor blocker use 
was lower in this group. Otherwise, the 2 groups 
were comparable (Table).
Mortality Risk
Both intensification events and hospitalizations were 
associated with significantly increased 1- year mor-
tality at all times during follow- up compared with no 
worsening (Figure 3). During follow- up, the hazard ratio 
of 1- year mortality for patients with an intensification 
event ranged from 1.48 to 1.99 compared with patients 
with no evidence of worsening. During the first 3 years, 
the hazard ratio of 1- year mortality was significantly 
higher for patients with a hospitalization compared 
with patients with an intensification event. Hereafter, 
no significant differences between mortality after the 2 
modes of worsening were observed, although the risk 
remained numerically higher after a hospitalization. Of 
the patients who died during follow- up, 57.2% died in 
hospital, 32.2% died at home, and the rest were not 
accounted for. In- hospital mortality was slightly higher 
for patients having a hospitalization (59.0%) than for 
patients having an outpatient intensification event 
(55.7%).
In the risk set matched analysis, 2910 patients died 
after an intensification event, corresponding to an ab-
solute 1- year risk of 18.0% (95% CI, 17.3%–18.7%), 
compared with 2741 patients after a HF hospitaliza-
tion, corresponding to an absolute 1- year risk of 22.6% 
(95% CI, 21.7%–23.5%), and 2437 matched controls, 
corresponding to an absolute 1- year risk of and 9.8% 
(95% CI, 9.5%–10.1%). The hazard ratio after the inten-
sification event was 1.75 (95% CI, 1.66–1.85; P<0.001), 
and it was 2.28 (95% CI, 2.16–2.41; P<0.001) after the 
first hospitalization, both compared with matched con-
trols. We observed similar tendencies in all subgroups. 
For patients initially diagnosed as outpatients, patients 
aged <70 years, and patients with COPD, there was no 
significant difference in mortality hazard after intensifi-
cation events and hospitalizations (Figure 4).
Intensification Events
Having an intensification event was associated with 
increased risk of HF hospitalization compared with 
the matched controls, although it was relatively 
rare, with a cumulative incidence of 8.8% (95% CI, 
8.0%–9.6%) after the first year, as illustrated in Figure 
S1A. Figure S1B illustrates that intensification events 
were associated with significantly increased risk of 
HF hospitalization- free mortality, implying that the 
Figure  3. Hazard ratios of 1- year mortality after first intensification event, heart failure (HF) hospitalization, or both, 
according to time since HF diagnosis.
Patients with a worsening event 1 year are not included in the analyses for subsequent years. The multivariable Cox models are 
conducted at the end of each year, which is why patients have to survive until then to be included in the analyses. Ndeaths indicates how 
many patients die within 1 year and the corresponding percentage of Npatients; and Npatients, number of patients in each group.
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increased mortality was not always preceded by HF 
hospitalization. During 5 years of follow- up, 84.1% of 
the patients with an intensification event had at least 
one hospitalization subsequently: 20.6% had a HF 
hospitalization, 41.3% had a non- HF cardiovascular 
hospitalization, and 76.6% had a noncardiovascular 
hospitalization. Among patients with a HF hospitali-
zation as first event, 88.6% had at least one more 
Figure  4. Absolute risk of 1- year mortality and hazard ratios after first intensification event or heart failure (HF) 
hospitalization compared with age- and sex- matched controls from the risk set in important subgroups.
The multivariable Cox models are conducted immediately after the worsening events, and all patients with a worsening event are 
included.
D
ow
nloaded from
 http://ahajournals.org by on A
ugust 20, 2020
J Am Heart Assoc. 2020;9:e016010. DOI: 10.1161/JAHA.119.016010 8
Madelaire et al Mortality After Intensified Diuretic Therapy
hospitalization: 50.1% HF, 45.6% non- HF cardiovas-
cular, and 75.4% noncardiovascular.
In an exploratory mortality analysis, we subdivided 
intensification events into types of intensification, also 
including initiating 40- mg/d furosemide equivalent (as 
opposed to the other analyses). All intensification event 
types were associated with increased mortality com-
pared with the matched controls, except for initiating 
40- mg/d furosemide equivalent, where no difference 
was observed (Figure S2).
DISCUSSION
Main Findings
In this nationwide cohort study, we observed that an 
outpatient intensification event was associated with 
a significantly increased mortality risk compared with 
patients with no signs of worsening. The risk associ-
ated with an intensification event was slightly lower 
compared with HF hospitalization, but outpatient in-
tensification was a common scenario and occurred 
more frequently than HF hospitalizations.
Previous Studies
Our results differed from what Okumura et  al ob-
served in the PARADIGM- HF trial population,3,4 where 
the 2 modes of HF worsening were equally frequent. 
In the present study, we registered patients with in-
tensification events regardless of dosage mainte-
nance (as opposed to the PARADIGM- HF trial, where 
changes had to be maintained for a month, which 
may have led to a lower incidence in that study). This 
may also partially explain why we observed a lower 
mortality risk associated with outpatient diuretic in-
tensification events compared with HF hospitalization. 
When including temporary changes (eg, <30 days), it 
is likely that some of these events, especially in the 
early phase of HF, reflect up titration of guideline 
medical therapy, device implantation, or both rather 
than actual HF progression. This is supported by 
the outpatient event- associated increase of mortal-
ity hazard ratio the longer the time since diagnosis. 
Furthermore, intravenously administrated diuretic 
therapy was not included in the definition of outpa-
tient intensified diuretic therapy in the present study; 
we only obtained data on oral therapy, because diu-
retic therapy is rarely administered intravenously in 
outpatient settings in Denmark. Such an event would, 
therefore, either be registered as a HF hospitalization 
(if lasting for a minimum of 2 days) or not be registered 
at all. Finally, Okumura et al3 had more clinical infor-
mation about the included patients and were able to 
deal with residual confounding in more comprehen-
sive ways than in this study, which may be a part of 
the explanation as well.
Although annual mortality for national HF popu-
lations is often described as one aggregate rate, the 
current analyses further emphasize that these survival 
statistics represent the homogenization of different 
populations with different outcomes. To improve out-
comes and individualize care requires accurate clinical 
reclassification when new events, such as intensifi-
cation of therapy, have occurred. However, it is nota-
ble that the selection of patients for matching to the 
intensification group herein identified a group with a 
high 1- year mortality of 10.4%, even without history of 
intensification or hospitalization. Previous work in the 
Danish population has demonstrated a 5- year mortal-
ity of only 14% in patients selected for age <70 years 
and absence of noncardiac diagnoses at the time of 
HF diagnosis.11
We observed some differences between patients 
who, within the first year, had an intensification event 
and a HF hospitalization. Patients with an intensifi-
cation event were slightly older and more frequently 
living in a nursing home, which may suggest that the 
threshold for hospital admission is higher among the 
frailest patients who are already in a facility with access 
to some care. Furthermore, the mechanisms behind 
the transition from well- compensated HF to acute de-
compensation are complex and remain obscure. Not 
all patients gain weight to any significant degree be-
fore hospital admission.12 It has been suggested that 
patients with HF may have impaired ability to inhibit 
sympathetic activation on increasing cardiac filling 
pressures, which may lead to a more drastic redistri-
bution of volume from the venous reservoir to the ef-
fective circulatory system and, thus, lead to congestion 
without increased bodyweight.13,14 By closely moni-
toring hemodynamics, it has been possible to detect 
changes weeks before a HF event, and with early med-
ical intervention, to reduce hospitalization rates.15–17  
These hemodynamic changes were also detected in 
patients who did not gain weight.18
Whether the increased mortality associated with an 
outpatient intensification event, observed in the present 
study, is attributable to the intensified diuretic therapy 
itself or rather the patients’ need of intensification can-
not be answered by the data. Although it might be ex-
plained by hypokalemia after intensification,19 it seems 
more likely that the intensification is a marker of clini-
cal instability, which confers the increased risk.6 In an 
observational cohort study, use of loop diuretics, and 
especially higher doses, was associated with more evi-
dence of congestion, more diabetes mellitus, and worse 
renal function as well as higher age. Higher doses of 
loop diuretics were associated with increased risk of 
outcomes, but in a fully adjusted model, it was not an 
independent predictor,20 suggesting that higher doses 
could be interpreted as a sign of more advanced fea-
tures of HF and congestion. In a recent randomized trial, 
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withdrawal of loop diuretics in a cohort of clinically sta-
ble patients with mild HF did not alter patient- reported 
dyspnea on the short- term.21 Moreover, the secondary 
outcome of HF- related events was similar between pa-
tients who maintained or discontinued diuretic therapy, 
although these events were relatively infrequent. Given 
that the use loop diuretics itself has an effect on adverse 
outcomes, a difference in HF- related events would have 
been expected. Nevertheless, the high incidence of in-
tensification events and the associated increased mor-
tality risk in the present study bring up serious concerns 
about whether the patients are being properly evaluated. 
In Denmark, when a patient has received a HF diagno-
sis, the patient will usually attend a specialized HF clinic 
to initiate evidence- based medical and device therapy. 
When receiving relevant therapy and in stable condi-
tion, the patient is referred back to his/her primary care 
physician without further follow- up in the HF clinic.22 An 
intensification event after this initial period will, therefore, 
often be managed by a primary care physician, who 
may not have the same awareness for potential rere-
ferral for a thorough HF evaluation as a cardiologist. On 
the basis of our data, it is not possible to determine the 
severity of progression, but it is likely that some patients 
with intensification events are progressing to stage D 
HF,7 without sufficient evaluation of exacerbating factors 
that could be addressed. Even if the trend cannot be 
reversed, evaluation for advanced therapies should be 
considered before patients have progressed to kidney 
and liver dysfunction, or palliative interventions may be 
appropriate. It is widely recognized that discussions to 
revise goals of care do not happen soon enough; some 
may be appropriately triggered by continued escalation 
of diuretics.
Subgroups
In subgroup analyses, we observed results like the overall 
population. However, for patients with an initial outpatient 
diagnosis of HF, patients aged <70 years at time of diag-
nosis, and patients with COPD at baseline, we observed 
no significant difference in 1- year mortality hazard after 
the 2 worsening events. Statistically, this is explained by 
broad CIs as a result of few events. It is likely that because 
of a high “baseline survival probability” among younger 
patients, this group is more affected by a worsening event 
than elderly patients. At the same time, younger patients 
may have a lower threshold for hospitalization attributable 
to a higher activity level and may therefore be hospitalized 
with less severe episodes compared with elderly patients, 
although this remains speculative. On the other hand, a 
poor baseline survival probability may be associated with 
less relative impact of HF worsening on mortality, as seen 
among patients with COPD. The results of the present 
study do not indicate that worsening HF should be man-
aged differently in the different subgroups.
Limitations
As the present study was conducted using data from 
administrative registers, some inherited limitations 
prevail. We recognize that the study population rep-
resents a selected group of patients with HF, in that 
we have excluded the frailest patients who did not 
survive the initial 120  days or did not start or toler-
ate ACEI/angiotensin receptor blocker, β blockers, or 
both and, thus, the results may not be applicable for 
patients experiencing events early after their HF diag-
nosis. The absence of data on left ventricular ejection 
fraction is a significant limitation, as analyses stratified 
for left ventricular ejection fraction would be valuable 
in evaluating patient characteristics and worsening 
trajectories. We acknowledge that our results are lim-
ited by the lack of data on clinical signs and laboratory 
results, which could have made more comprehensive 
adjustment and further stratified analyses possible. 
We chose to define intensification events by certain 
jumps in dosage, based on both clinical practice (1) 
initiating furosemide- equivalent therapy with 80 mg/d, 
usually administered as 40 mg twice daily, and adding 
thiazide diuretic therapy when furosemide becomes 
insufficient and (2) doubled dosage, on the basis of 
the DOSE (Diuretic Optimization Strategies Evaluation) 
trial protocol.23 We acknowledge that these dosage 
jumps are still relatively arbitrary, and other dosages 
could have been chosen and this would likely influence 
the results. Despite these limitations, the systematic 
enrollment and follow- up of this large population and 
the high positive predictive value of the HF diagnosis in 
the Danish registers9 provide unique data that add the 
important perspective of a nontrial population.
CONCLUSIONS
Among patients with HF and ACEI/angiotensin recep-
tor blocker and β- blocker therapy at 120 days after di-
agnosis, outpatient diuretic intensification events were 
frequent and were associated with a significantly el-
evated mortality risk. Although HF hospitalization was 
associated with an even higher risk, patients with an 
outpatient intensification event should receive as care-
ful a reevaluation for optimization of drug therapy and 
consideration of advanced options as patients who are 
hospitalized for worsening HF.
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Figure S1. Competing risk analysis showing cumulative incidence of HF hospitalization after 
a first intensification event compared to matched controls from the risk set (a), and 
cumulative incidence of HF hospitalization-free mortality after a first intensification event 
compared to matched controls from the risk set (b).  
a) 
 
b) 
 
D
ow
nloaded from
 http://ahajournals.org by on A
ugust 20, 2020
 
 
Figure S2. Cumulative incidence of all cause mortality after a first intensification event 
compared to matched controls from the risk set, stratified after type of intensification.  
0: No intensification of diuretic therapy  
1: Increased furosemide equivalent from 0 mg/day to 40mg/day (Not included in main analyses)  
2: Increased furosemide equivalent from 0 mg/day to 80mg/day  
3: Doubled dosage of furosemide equivalent to a minimum of 160mg/day  
4: Thiazide diuretic therapy added to a minimum of 160mg/day furosemide equivalent   
 
D
ow
nloaded from
 http://ahajournals.org by on A
ugust 20, 2020
